Initial Testing (stage 1) of Lapatinib by the Pediatric Preclinical Testing Program

Overview

Journal Pediatr Blood Cancer

Specialties Hematology
Oncology
Pediatrics

Date 2009 Jun 26

PMID 19554571

Citations 18

Authors

Richard Gorlick

E Anders Kolb

Peter J Houghton

Christopher L Morton

Doris Phelps

Paula Schaiquevich

Clinton Stewart

Stephen T Keir

Richard Lock

Hernan Carol

C Patrick Reynolds

John M Maris

Jianrong Wu

Malcolm A Smith

Affiliations

Soon will be listed here.

Abstract

Background: Lapatinib is a small molecule reversible tyrosine kinase inhibitor of EGFR and ErbB2 that shows in vitro and in vivo activity against a range of EGFR and ErbB2-dependent adult cancer cell lines and that has clinical efficacy against ErbB2-overexpressing breast cancer.

Methods: Lapatinib was tested against the cell lines of the PPTP in vitro panel at concentrations ranging from 1.0 nM to 10.0 microM. Lapatinib was tested against the xenografts of the PPTP in vivo panels using a twice-daily oral administration schedule for 6 weeks (5 days on, 2 days off) at a dose of 160 mg/kg (320 mg/kg/day). Lapatinib pharmacokinetic parameters were determined in scid(-/-) mice.

Results: The median IC(50) value for lapatinib against the entire PPTP cell line panel was 6.84 microM (range, 2.08 to >10.0 microM). Lapatinib was well tolerated in vivo, with toxicity in only 1.5% of the treated animals. Lapatinib induced significant differences in EFS distribution compared to controls in 1 of 41 xenografts tested. No objective responses were observed in any of the solid tumor panels or in the ALL panel. Lapatinib systemic exposure was consistent with previously observed values.

Conclusions: Lapatinib has little activity against the xenografts of the PPTP's in vivo panel, and its in vitro activity occurs at concentrations above those associated with specific EGFR/ErbB2 inhibition. These results likely reflect lack of ErbB2 overexpression in the models studied and suggest that adult and pediatric cancers may fundamentally differ in the applicability of EGFR family members as therapeutic targets.

Citing Articles

Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario.

Candido M, Medeiros M, Veronez L, Bastos D, Oliveira K, Pezuk J Pharmaceutics. 2023; 15(2).

PMID: 36839989 PMC: 9966033. DOI: 10.3390/pharmaceutics15020664.

Engages an Inhibitory Protein Network to Downregulate Expression upon DNA Damage.

Palombo R, Paronetto M Cancers (Basel). 2022; 14(6).

PMID: 35326688 PMC: 8946712. DOI: 10.3390/cancers14061537.

Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models.

Bandyopadhyay A, Favours E, Phelps D, Pozo V, Ghilu S, Kurmashev D Pediatr Blood Cancer. 2017; 65(2).

PMID: 29080385 PMC: 5739936. DOI: 10.1002/pbc.26870.

A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program.

Jones L, Carol H, Evans K, RICHMOND J, Houghton P, Smith M Leukemia. 2016; 30(11):2133-2141.

PMID: 27416986 DOI: 10.1038/leu.2016.192.

The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma.

Bid H, Phelps D, Xaio L, Guttridge D, Lin J, London C Mol Cancer Ther. 2016; 15(5):1018-28.

PMID: 26908627 PMC: 4873398. DOI: 10.1158/1535-7163.MCT-15-0567.

References

Hughes D, Thomas D, Giordano T, Baker L, McDonagh K . Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res. 2004; 64(6):2047-53. DOI: 10.1158/0008-5472.can-03-3096. View

Dancey J . Epidermal growth factor receptor inhibitors in non-small cell lung cancer. Drugs. 2007; 67(8):1125-38. DOI: 10.2165/00003495-200767080-00003. View

Friedman H, COLVIN O, Skapek S, Ludeman S, ELION G, Schold Jr S . Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res. 1988; 48(15):4189-95. View

Slamon D, Godolphin W, Jones L, Holt J, Wong S, Keith D . Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244(4905):707-12. DOI: 10.1126/science.2470152. View

Rusnak D, Alligood K, Mullin R, Spehar G, Arenas-Elliott C, Martin A . Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif. 2007; 40(4):580-94. PMC: 6495710. DOI: 10.1111/j.1365-2184.2007.00455.x. View

Liem N, Papa R, Milross C, Schmid M, Tajbakhsh M, Choi S . Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood. 2004; 103(10):3905-14. DOI: 10.1182/blood-2003-08-2911. View

Rusnak D, Lackey K, Affleck K, Wood E, Alligood K, Rhodes N . The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 2002; 1(2):85-94. View

Akatsuka T, Wada T, Kokai Y, Kawaguchi S, Isu K, Yamashiro K . ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer. 2002; 94(5):1397-404. DOI: 10.1002/cncr.10360. View

Robinson D, Wu Y, Lin S . The protein tyrosine kinase family of the human genome. Oncogene. 2000; 19(49):5548-57. DOI: 10.1038/sj.onc.1203957. View

10.

Graham C, Tucker C, Creech J, Favours E, Billups C, Liu T . Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clin Cancer Res. 2006; 12(1):223-34. DOI: 10.1158/1078-0432.CCR-05-1225. View

11.

Kurmasheva R, Harwood F, Houghton P . Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors. Mol Cancer Ther. 2007; 6(5):1620-8. DOI: 10.1158/1535-7163.MCT-06-0646. View

12.

Konecny G, Pegram M, Venkatesan N, Finn R, Yang G, Rahmeh M . Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006; 66(3):1630-9. DOI: 10.1158/0008-5472.CAN-05-1182. View

13.

Gilbertson R . ERBB2 in pediatric cancer: innocent until proven guilty. Oncologist. 2005; 10(7):508-17. DOI: 10.1634/theoncologist.10-7-508. View

14.

Bredel M, Pollack I, Hamilton R, James C . Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin Cancer Res. 1999; 5(7):1786-92. View

15.

Tamura S, Hosoi H, Kuwahara Y, Kikuchi K, Otabe O, Izumi M . Induction of apoptosis by an inhibitor of EGFR in neuroblastoma cells. Biochem Biophys Res Commun. 2007; 358(1):226-32. DOI: 10.1016/j.bbrc.2007.04.124. View

16.

Xia W, Mullin R, Keith B, Liu L, Ma H, Rusnak D . Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene. 2002; 21(41):6255-63. DOI: 10.1038/sj.onc.1205794. View

17.

Houghton P, Morton C, Kolb E, Lock R, Carol H, Reynolds C . Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2007; 50(1):37-45. DOI: 10.1002/pbc.21214. View

18.

Peterson J, Tucker C, Favours E, Cheshire P, Creech J, Billups C . In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. Clin Cancer Res. 2005; 11(19 Pt 1):6950-8. DOI: 10.1158/1078-0432.CCR-05-0740. View

19.

Frgala T, Kalous O, Proffitt R, Reynolds C . A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther. 2007; 6(3):886-97. DOI: 10.1158/1535-7163.MCT-04-0331. View

20.

Houghton P, Morton C, Tucker C, Payne D, Favours E, Cole C . The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer. 2006; 49(7):928-40. DOI: 10.1002/pbc.21078. View